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FR255734, a Humanized, Fc-Silent, Anti-CD28
Antibody, Improves Psoriasis in the SCID
Mouse-Psoriasis Xenograft Model
Siba P. Raychaudhuri1,2,3, Smriti Kundu-Raychaudhuri1, Kouichi Tamura4, Taro Masunaga4, Kaori Kubo4,
Kaori Hanaoka4, Wen-Yue Jiang1, Leonore A. Herzenberg1 and Leonard A. Herzenberg1
In psoriasis, CD28/B7 costimulatory molecules are well characterized. Here, using the severe combined
immunodeficient (SCID) mouse-psoriasis xenograft model, we report therapeutic efficacy of a humanized anti-
CD28 monoclonal antibody (FR255734; Astellas Pharmaceuticals Inc., Tokyo, Japan). Transplanted psoriasis
plaques on the SCID mouse were treated weekly for 4 weeks with intraperitoneal injections of FR255734 at 10, 3,
and 1-mgkg1 doses. Groups treated with doses of 10 and 3mgkg1had significant thinning of the epidermis
and reduced HLA-DR-positive lymphocytic infiltrates. The length of the rete pegs changed from 415.2±59.6 to
231.4±40.4 mm (Po0.005) in the 10-mgkg1 group, and from 323.4±69.6 to 237.5±73.6 mm in the 3-mgkg1 group
(P¼ 0.002). Positive controls treated with CTLA4-Ig and cyclosporine had significant histological improvement,
whereas plaques treated with saline and isotype controls (human and mouse IgG2) remained unchanged.
In vitro studies have shown that FR255734 effectively blocked T-cell proliferation and proinflammatory cytokine
production. These observations warrant studies to evaluate the efficacy of FR255734 in human autoimmune
diseases.
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INTRODUCTION
Optimal activation of T cells requires interactions of T-cell
receptor with major histocompatibility complex-peptide
antigens, and the engagement of a costimulatory receptor
with its respective ligand. A number of costimulatory
molecules have been shown to influence T-cell activation.
The most well-characterized T-cell costimulatory ligands are
CD28 and cytotoxic T lymphocyte-associated antigen-4
(CTLA4) (CD152), which engage CD80 and CD86 receptors
on antigen-presenting cells (APCs) (Mueller et al., 1989;
Linsley et al., 1991). Among these, a principal signal is
delivered by engagement of CD28 on T cells with CD80 (B7-1)
and CD86 (B7-2) on APCs. This process enhances T-cell
activation by stabilization of cytokine mRNA and upregulation
of antiapoptotic genes. In contrast, CTLA4-Ig binds to B7-1
and B7-2 molecules on APCs and blocks the CD28-mediated
costimulatory signal for T-cell activation. Thus, the B7
family of molecules on APCs regulates T-cell activation by
delivering antigen-independent stimulatory signals through
CD28 and inhibitory signals through CD152. This unique
mechanism of T-cell activation has provided several
target molecules for therapeutic manipulation of immune
responses.
The effectiveness of costimulatory signal blockade as a
therapeutic device was shown over a decade by demonstrat-
ing that CTLA4-Ig inhibited graft rejection and induced long-
term tolerance in mice (Lenschow et al., 1992). Encouraging
results in animal models have led to successful clinical trials
with CTLA4-Ig in psoriasis and rheumatoid arthritis (Abrams
et al., 1999; Kremer et al., 2003; Genovese et al., 2005). In
this study we took an alternative approach to develop
immunomodulatory drug by manipulating CD28CD80/86
interactions using a monoclonal anti-CD28 antibody
(FR255734) prepared by Fujisawa Pharmaceutical Co., Ltd.
(now Astellas Pharmaceuticals Inc., Tokyo, Japan). FR255734
is a humanized IgG2k anti-human CD28 antibody that has
the complementary determining regions of the mouse anti-
human monoclonal antibody TN228 and the Fc domain of
human IgG2M3 in which two amino acid mutations (V234A,
G237A) have been introduced into the human g2 chain to
eliminate binding of the antibody to FcgR. The original
TN228 cell line was generated by immunizing BALB/c mice
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with human CD28-transfected mouse fibroblast L cells, and
fusing immune splenocytes with P3 U1 myeloma cells.
The purified molecule consists of two heavy chains and
two light chains, which are 447 amino-acid residues
(C2177H3358N575O669S19; MW 48898.64) and 218
amino-acid residues (C1043H1628N279O342S7; MW
23772.21) in length, respectively. FR255734 binds to a
human CD28mouse IgG Fc fusion protein (Kd¼3.72
108) and inhibits proliferation of human T cells stimulated
with anti-CD3 and P815/human CD80þ cells in a concen-
tration-dependent manner. FR255734 does not cross-react
with mouse CD28 (Shiao et al., 2007). Here, we are
providing results of both in vivo and in vitro studies
documenting the therapeutic efficacy of FR255734.
RESULTS
In vitro studies—Regulatory role of FR255734 on activated
T cells
Effect of FR255734 on T-cell proliferation. Activated human
T lymphocytes purified from human peripheral blood mono-
nuclear cells (PBMCs) were used for this assay. Stimulation by
anti-human CD3 mAbþ human-CD80/P815 strongly in-
duced proliferation of T cells, but anti-CD3mAb alone or
human-CD80/P815 alone did not (data not shown), indicat-
ing that proliferation depends on CD28 costimulatory
signaling. Humanized, Fc-silent anti-CD28 antibody inhibited
T-cell proliferation in a dose-dependent manner (Figure 1a).
Maximum suppression was obtained by the 300-ngml1
dose and at that dose it reached the plateau effect. Isotype
controls (mouse IgG2 and human IgG2) did not show
inhibition of T-cell proliferation. The Figure 1a showed
that isotype control, mouse IgG2, did not inhibit T-cell
proliferation. Human IgG2 had the similar non-inhibitory
effect (data not shown).
Cytokine assay by ELISA to investigate the inhibitory effect
of FR255734 on T-cell function. Supernatants of PBMCs
stimulated with anti-human CD3/CD28 antibodies and
tetanus toxoid, a recall antigen were used for this assay. As
expected CD3CD28 antibody stimulation induced IFN-g and
IL-2 secretion (Figure 1b). FR255734 antibody inhibited IFN-g
secretion induced by CD3–CD28 stimulation (Po0.005,
t-test) (Figure 1b), whereas isotype controls (mouse and human
IgG2) did not inhibit IFN-g production. These results are
summary of experiments using PBMCs from six individuals.
Each experiment was performed in triplicate from each
individual. Effect of this antibody was similar to the inhibitory
effect of CTLA4-Ig (Po0.005, t-test). When only CD3
antibody was used for stimulation, IFN-g production by
PBMCs was p30 pgml1, which was similar to that by
unstimulated PBMCs (Figure 1b), indicating that CD28 was
necessary for proper stimulatory effects. FR255734 has
similar effects on IFN-g production by tetanus toxoid, a
recall antigen (732 ngml1) stimulated PBMC (Po0.005,
t-test) (Figure 1c). Experiments were performed using PBMCs
from six individuals who had been vaccinated with tetanus
toxoid for other purposes. Each experiment was performed in
triplicate. FR255734 also had significant inhibitory effects on
IL-2 production by CD3CD28 and tetanus toxoid-stimulated
PBMCs (Po0.005, t-test) (Figure 1d and e). Similar inhibitory
effects were observed with CTLA4-Ig. Isotype controls (mouse
and human IgG2) did not show inhibitory effects on IL-2 and
IFN-g production by CD3CD28 or tetanus-stimulated PBMCs
(P¼0.9, t-test) (Figure 1).
In vivo studies
Evaluation of therapeutic efficacy of FR255734 using the
SCID mouse-psoriasis xenograft model. Shave biopsies
(2.52.5 cm) were obtained from active plaques located
on the thigh or arm of psoriatic patients. Each piece of biopsy
was divided into four equal parts of approximately 1 cm2 size.
Eighty severe combined immunodeficient (SCID) mice were
transplanted using biopsies obtained from 20 patients. This
study includes 60 successful grafts collected from these 20
psoriasis patients. The protocol for selecting FR255734,
saline, isotype controls, or the positive control treatment of
the successful grafts obtained from a single patient was based
on the principle that FR255734 should be evaluated against
the controls in the grafts of the same patients as many times as
it is possible. If two grafts from the same patients were
successful, one was treated with FR255734 and the other one
with either positive or negative controls; if three grafts were
successful, one graft was treated with a positive control in
addition to FR255734, and the other one with saline/isotype
control. In case of all four successful grafts, treatment of
fourth graft was by a different dose or the same dose of
FR255734. In case of only one successful graft, any of the
agents from the study groups or the control groups was used.
However, like any other mouse studies, some of the
transplanted mice died in the middle of the study and
additional grafts had to be recruited according to the need of
a particular group. First, we evaluated the efficacy of
FR255734 at the dose of 10mg kg1 body weight (group A).
This dose was selected on the basis of our in vitro studies.
Twenty-four successful grafts collected from eight patients
were used for the controls (n¼ 12) and for group A
(FR255734 10mgkg1, n¼12). To obtain proper controls
for group A (FR255734, 10mg kg1), six grafts each from the
same patients were treated with saline/isotype control and
10mgkg1 FR255734, four grafts each with CTLA4-Ig and
10mgkg1 FR255734, and two grafts each with cyclosporine
and 10mgkg1 FR255734. Once we observed therapeutic
efficacy of FR255734 at the dose of 10mg kg1, we looked
for therapeutic efficacy of FR255734 at the dose of 3mg kg1
(group B) and 1mg kg1 (group C) body weight. In group B
(FR255734, 3mg kg1, n¼ 8), grafts treated from the same
patients were 3 and 2, respectively, for saline/isotype control
and CTLA4-Ig. In group C (FR255734, 1mg kg1, n¼ 8),
grafts treated from the same patients were 3, 2, and 2,
respectively for saline, CTLA4-Ig, and cyclosporine. For each
graft, biopsies were taken before and after treatment and
histological changes were compared.
Table 2 shows various treatment groups, doses, and
schedules. Transplanted plaques treated with FR255734
at 10 and 3mgkg1 had significant clinical and histo-
logical improvement compared with controls. Histological
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improvement in the treated plaques was evidenced by
reduction of hyperkeratosis, acanthosis, and lymphomono-
nuclear cellular infiltrates (Figure 2). In plaques treated with
10 and 3mgkg1, there was significant thinning of the
epidermis (Table 1). The length of the rete pegs changed
from 415.2±59.6 to 231.4±40.4 mm (Po0.005) with the
10-mg kg1 dose, and 323.4±69.6–237.5±73.6 mm with the
3-mg kg1 dose (P¼0.002, paired t-test; Table 1). Plaques
treated with 1mg kg1 FR255734 did not show significant
improvement.
Rete peg lengths in the pretreated plaques and 4 weeks
following treatment with mouse IgG2 (n¼5) were 276±101
and 286±62 mm, respectively. Similarly, rete peg lengths in
the pretreated plaques and 4 weeks following treatment with
human IgG2 (n¼5) were 300±43 and 284±30 mm,
respectively. Transplanted psoriasis grafts treated with these
istoype controls did not have any significant histopathologi-
cal or immunological improvement (P40.2, paired t-test;
Table 1; Figure 3). In the saline control group, the before- and
after-therapy rete peg lengths were 345.6±105.1 and
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Figure 1. FR255734 inhibits T-cell proliferation and cytokine production. (a) Humanized, Fc-silent anti-CD28 antibody inhibited T-cell proliferation in a dose-
dependent manner. T cells were cultured with antihuman CD3 and CD28 antibody and human CD80/P815. Several doses of FR255734 (3–10,000 ngml1) were
added to the culture to determine the inhibitory effect. Maximum inhibitory effect was seen at 300 ngml1 dose where this effect reached a plateau. Results were
expressed as mean±SD of triplicate wells of six individuals. Mouse IgG2 isotype control did not inhibit T-cell proliferation. Each experiment was performed
in triplicate. (b) FR255734 at 300 ngml1 significantly inhibited IFN-g production by anti-human CD3CD28 antibody stimulation. CTLA4-Ig, a positive
control, showed similar inhibitory effect. Unstimulated PBMCs produced very small amount of IFN-g p30pgml1 compared with CD3CD28 stimulated
PBMCs. Human IgG2 and mouse IgG2 isotype controls did not inhibit IFN-g production. (c) FR255734 at 300 ngml1 dose inhibited IFN-g production
significantly after tetanus toxoid stimulation. CTLA4-Ig had shown similar inhibition. Unstimulated PBMCs produced very small amount was p30 pgml1
of IFN-g compared with tetanus toxoid stimulated PBMCs. Each experiment was performed in triplicate. Human IgG2 and mouse IgG2 isotype controls did
not inhibit IFN-g production. (d) FR255734 antibody at 300 ngml1 dose inhibited IL-2 production significantly after CD3CD28 antibody stimulation. CTLA4-Ig
showed similar effect. Unstimulated PBMCs produced very small amount,p20 pgml1, of IL-2 compared with CD3CD28 antibody-stimulated PBMCs. Human
IgG2 and mouse IgG2 isotype controls did not inhibit IL-2 production. (e) FR255734 antibody at 300 ngml1 inhibited IL-2 production significantly after tetanus
toxoid stimulation. CTLA4-Ig also significantly inhibited IL-2 production. Unstimulated PBMCs produced very small amount, p20 pgml1, of IL-2 compared
with tetanus toxoid-stimulated PBMCs. Results are expressed as mean±SD of results from six individual experiments. Each experiment was performed in
triplicate. Human IgG2 and mouse IgG2 isotype controls did not inhibit IL-2 production.
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322.9±108.6mm (P40.1, paired t-test). The control plaques
treated with isotype controls and saline for the same duration
did not show any significant improvement. These observa-
tions imply that histological improvement was specifically
due to therapeutic efficacy of FR255734. Also, FR255734 not
therapeutically effective at the dose of 1mg kg1 further
suggests that therapeutic efficacy of FR255734 was not
because of the class effect of human and mouse IgG2. The
transplanted psoriasis plaques are reported to lose the
characteristic features of psoriasis with time. To address this
variation, we kept untreated plaques and plaques treated with
saline as controls. We observed that immunological and
histological features of psoriasis were maintained in the
transplanted plaques for 4–6 months. Other investigators have
similar observations as well. In this study, we completed all
experimental works in each mouse within 8 weeks of
transplantation.
We observed that inflammatory infiltrates (hematoxylin
and eosin staining), HLA-DR-positive lymphocytic infiltrates,
and dermal CD3þ lymphocytic infiltrates were significantly
reduced in plaques treated with FR255734 at the effective
doses of 10 and 3mg kg1 body weight. Figure 2 demon-
strates marked reduction of CD3þ lymphocytic infiltrates in
graft treated with FR255734 at the dose of 10mg kg1 per
week. In pre- and post-treated tissues, CD3þ lymphocytic
infiltrates were calculated by using a reticule as described
earlier (Raychaudhuri et al., 1998, 1999, 2001, 2004). In
group A plaques (FR255734, 10mg kg1), the number of the
CD3þ lymphocytes per square millimeter of dermis reduced
from 166±51 to 22±8 following 28 days of treatment
(Po0.01, t-test). The number of the CD3þ lymphocytes in
pretreated plaques and in plaques 4 weeks following
treatment with the isotype control, mouse IgG2 (n¼5), was
172±30 and 152±36, respectively, per square millimeter of
dermis. In pretreated plaques and in plaques 4 weeks
following treatment with the isotype control, human IgG2
(n¼5), CD3þ lymphocytes per square millimeter of the
dermis were 168±43 and 155±30, respectively. In the
saline control group, the number of CD3þ lymphocytes per
square millimeter of dermis before and after treatment was
158±48 and 140±42. Changes in the number of CD3þ
lymphocytes per square millimeter of dermis in pre- and
post-treated transplanted psoriasis graft following treatment
Table 1. Pre- and post-treatment rete peg length (thickness of epidermis) in different study groups
Rete peg length (avg.(lm)±SD)
Group (no. of mice) Treatment Dose Pre-treat Post-treat P-value
A (12) FR255734 10mg kg1 415.2±59.6 231.4±40.4 Po0.005
B (8) FR255734 3mg kg1 323.4±69.6 237.5±73.6 P=0.002
C (8) FR255734 1mg kg1 283±45.8 267.4±71.5 P=0.24
D (5) Human IgG2 10mg kg1 300±43 284±30 P=0.25
E (5) Mouse IgG2 10mg kg1 276±101 286±62 P=0.24
F (12) N.Saline 10ml kg1 345.6±105.1 322.9±108.6 P=0.1
G (6) CTLA4-Ig 10mg kg1 360.6±100.4 209.5±60.4 P=0.001
H(4) Cyclosporine 2mg kg1 360.5±104.8 171.2±55.1 Po0.01
N.Saline, normal saline; CTLA4-Ig, cytotoxic T lymphocyte-associated antigen-4-Ig.
a b
Figure 2. Histopathological and immunohistochemical studies in pre- and
post-treated biopsies of transplanted psoriasis plaques. Transplanted
psoriasis graft on a SCID mouse was treated with FR255734 at 10 ngml1 per
week for 4 weeks. Pretreatment (a) and post-treated (b) tissues were stained for
expression of CD3 and counterstained with hematoxylin. Histopathological
studies of the post-treated (b) graft demonstrated significant thinning of the
epidermis and marked reduction of CD3-positive infiltrates. Dark brown
positive cells marked by arrows indicate CD3þ lymphocytes. Original
magnification  200.
a b
Figure 3. Immunohistochemical studies for CD3þ lymphocytes in pre (a)
and post (b) treated biopsies from a psoriasis graft treated with human IgG2.
Compared with Figure 2 there is no histopathological improvement in the
post-treated (b) section. In both pre- (a) and post-treated (b) biopsies, the same
degree of epidermal thickening typical for psoriasis along with marked
CD3þ lymphocyte infiltrates is seen within dermis and epidermis. Black
arrows indicate brown-colored CD3þ lymphocytes.
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with normal saline and isotype controls (human and mouse
IgG2) were not of any statistical significance. In Figure 3,
immunohistochemical staining for CD3þ lymphocyte de-
monstrates that the degree of CD3þ lymphocyte infiltrates
remained unchanged in pre- and post-treated biopsies
following treatment with human IgG2. Similarly, marked
reduction of tumor necrosis factor-a (TNF-a) expression in
dermal infiltrates, and reduction of ICAM-1 in the lesional
blood vessels were seen in psoriatic grafts treated with
FR255734 at doses of 10 and 3mgkg1 body weight. Figures
4 and 5 demonstrate marked reduction of TNF-a expression
in dermal infiltrates, and reduction of ICAM-1 in the lesional
blood vessels in grafts treated with FR255734 at the dose of
10mg kg1 per week. TNF-a in psoriasis is mainly expressed
in dermal dendrocytes, monocytes, and mast cells, and can
be expressed in the keratinocytes and activated T lymphocyte
infiltrates (Nickoloff et al., 1991; Ackermann and Harvima,
1998). We only counted discrete dermal TNF-a-positive cells
as shown Figure 4. The large size of the TNF-a-positive cells
in this figure suggests that these cells are likely mast cells or
monocytes. In group A plaques (FR255734, 10mg kg1), the
number of the TNF-a-positive cells per square millimeter of
dermis reduced from 60±22 to 8±8 following 28 days of
treatment (Po0.01, t-test). In the saline control group, the
numbers of the TNF-a-positive cells per square millimeter of
dermis before and after treatment were between 68±18 and
58±16 (P¼0.1, t-test). Because of non-availability of tissues,
staining for TNF-a could only be performed in two grafts
treated with human IgG2. These pre- and post human IgG2-
treated biopsies did not show significant difference in the
numbers of TNF-a-positive cells. Because of non-availability
of tissues, staining for ICAM-1 was not performed in grafts
treated with human and mouse IgG2. In saline controls,
marked expression of ICAM-1 was noticed in both pre- and
post-treated biopsies.
To substantiate this observation, we further investigated
whether similar improvement of psoriasis could be attained
by blocking interaction of CD28/B7 with CTLA4-Ig. Results in
Table 2 demonstrate that, as expected CTLA4-Ig is also
therapeutically effective for psoriasis in this SCID mouse-
psoriasis xenograft model. Similarly cyclosporine, a known
immunomodulatory treatment for psoriasis, was found to be
therapeutically effective in this model as well (Table 1). These
two treatment groups were positive control groups. Mice
remained healthy and active throughout the study period. No
weight loss, lack of activity, or infection occurred during the
study period and 3 months after the experiments were
concluded. Thus, there were no apparent toxic detected
despite the inhibitory effects on T-cell stimulation.
DISCUSSION
Psoriasis is a multifactorial disease of unknown etiology that
affects approximately 2% of the global population (Farber
and Peterson, 1961; Raychaudhuri and Farber, 2001).
Psoriatic lesions are characterized by a clinical triad
consisting of skin induration, scaling, and erythema. Histo-
logical findings include inflammation, abnormal keratinocyte
a b
Figure 5. ICAM-1 expression in pre- and post-treated biopsies following
treatment with FR255734, 10mg kg1 per week for 4 weeks. Pretreatment (a)
and post-treated (b) tissues were stained for ICAM-1 with a rabbit anti-human
polyclonal antibody and counterstained with hematoxylin. Post-treated (b)
graft demonstrated significant thinning of the epidermis and marked
reduction of ICAM-1 in the blood vessels. Brown positive cells marked by
black arrows indicate expression of ICAM-1 on the luminal endothelial cells
on both sides of a blood vessel extending from deep dermis to the papillary
dermis. Original magnification  200.
a b
Figure 4. TNF-a-positive dermal infiltrates in pre- and post-treated biopsies
following treatment with FR255734, 10mg kg1 per week for 4 weeks.
Pretreatment (a) and post-treated (b) tissues were stained for TNF-a with a
rabbit anti-human polyclonal antibody and counterstained with hematoxylin.
Post-treated (b) graft demonstrated significant thinning of the epidermis and
marked reduction of TNF-a-positive dermal infiltrates. Brown positive cells
marked by arrows indicate intracellular expression of TNF-a. Original
magnification  400.
Table 2. Study treatment outline
Group No. Treatment Dose Schedule Volume
A 12 FR255734 10mg kg1 Once a week 10ml kg1
B 8 FR255734 3mg kg1 Once a week 10ml kg1
C 8 FR255734 1mg kg1 Once a week 10ml kg1
D 5 Human IgG2 10mg kg1 Once a week 10ml kg1
E 5 Mouse IgG2 10mg kg1 Once a week 10ml kg1
F 12 Saline Saline Once a week 10ml kg1
G 6 CTLA4-Ig 10mg kg1 Once a week 10ml kg1
H 4 Cyclosporine 2mg kg1 Thrice a week 10ml kg1
CTLA4-Ig, cytotoxic T lymphocyte-associated antigen-4-Ig.
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proliferation/terminal differentiation, and dermal angiogen-
esis. Inflammatory infiltrates, particularly pronounced at
the dermal–epidermal junction, consist largely of activated
T cells and APCs and precede development of epidermal
hyperproliferation. Upregulation of B7-1 (CD80) and B7-2
(CD86) by dendritic cells in psoriatic lesions suggests a
critical role for the CD28/B7 costimulatory system in the
pathogenesis of psoriasis, and provides logistics for develop-
ment of therapies targeting these key immunoregulatory
molecules (De Rie et al., 1996; Gottlieb et al., 2004). The aim
of this study is to develop novel therapeutic approach for
T-cell autoimmune conditions by blocking the CD28/B7
costimulatory interactions, a critical molecular event for
functional activation of the T cells.
Here, in a series of in vitro studies, we have demonstrated
that FR255734 effectively inhibits CD28/B7 costimulation
and T-cell activation. This antibody inhibits T-cell prolifera-
tion (Figure 1a), proinflammatory cytokines, IL-2 and IFN-g
production (Figure 1b–e). For in vivo studies, we have used
the SCID mouse-psoriasis xenograft model (Nickoloff et al.,
1995). Clinical, histopathological, and immunological fea-
tures of human psoriasis plaque remain intact for 4–6 months
in this model (Raychaudhuri et al., 2001). T-cell infiltrates in
the transplanted psoriasis grafts on SCID mice express
activation markers (HLA-DR and CD69); and dendritic
cells and activated T cells express CD80 and CD86, the
ligands of the costimulatory molecules. Upregulation and
maintenance of CD80/CD86 molecules in transplanted grafts
suggest that the CD28/B7 costimulatory system is functional
and plays a critical role in the pathogenesis of psoriasis.
Several studies, including that by our group, have success-
fully used this model to evaluate the therapeutic efficacy of
established and novel therapies specifically targeted against
key biological events associated with pathogenesis of
psoriasis (Boehncke et al., 1999; Schon et al., 2002;
Raychaudhuri et al., 2004). Thus, this model is unique, as it
allows to evaluate the therapeutic efficacy of a pharmaco-
logical agent by treating the transplanted human psoriatic
plaques.
In this study, FR255734, an antagonist of the CD28
molecule, demonstrated significant therapeutic efficacy for
psoriasis. As shown in the Table 1 and Figures 2, 4, and 5,
following 4 weeks of therapy with FR255734, we noticed
significant thinning of the epidermis along with reduced
infiltrates of CD3þ lymphocytes and downregulation of
inflammatory markers such as TNF-a and ICAM-1. It is
believed that in psoriasis/psoriatic arthritis, similar to other
autoimmune diseases, memory T cells are selectively
recruited through tight control of homing molecules at the
site of the disease. Subsequent recruitment, these specific
memory T cells interact with a hypothetical antigen, which
activates these cells and initiates signal transduction cascades
for upregulation of various inflammatory cytokines (TNF-a
and IFN-g). Our results clearly demonstrate significant
reduction of CD3þ T cells in the treated plaques compared
with controls. These observations suggest that the antagonism
to the CD28/B7 costimulatory system by FR255734 is likely
responsible for improvement of psoriasis. Upregulation of
TNF-a and ICAM-1 in psoriasis plays a critical role in the
pathogenesis of psoriasis. Role of TNF-a and ICAM-1 in
psoriasis is further substantiated by clinical evidence that
treatment based on antagonizing TNF-a and ICAM-1 is highly
effective in psoriasis (Gottlieb et al., 2000; Chaudhari et al.,
2001). Thus, downregulation of these two critical inflamma-
tory mediators following treatment with FR255734 suggests
that FR255734, by regulating T-cell activation signals,
eventually inhibits inflammatory cascades associated with
the pathogenesis of psoriasis.
In conclusion, we have demonstrated by in vitro studies
that FR255734 effectively inhibits cell activation by blocking
CD28/B7 costimulatory interactions. This encouraged us to
evaluate the clinical efficacy of FR255734 in T-cell-mediated
disease. To evaluate the therapeutic efficacy of FR255734 as
a costimulatory antagonist, we have used the SCID mouse
model of psoriasis. We noticed significant improvement in
the thickness of the epidermis and reduction in infiltrates in
the FR255734-treated group (Po0.005 at 10mg kg1, and
P¼0.002 at 3mg kg1). In the normal saline-treated group
and isotype controls (negative controls), epidermal thickness
and the amount of infiltrates remained unchanged (Table 1;
Figure 3). Transplanted plaques treated with cyclosporine and
CTLA4-Ig (positive controls) also demonstrated significant
histopathological improvement. The results of our study
substantiate a novel approach for treatment of T-cell-
mediated diseases by specifically manipulating the interac-
tion of CD28 and B7 costimulatory molecules of activated T
cells. Also, observations of this study provide the basis for
clinical trials with FR255734 in diseases known for an active
role of T cells such as psoriasis, rheumatoid arthritis, multiple
sclerosis, and others.
MATERIALS AND METHODS
In vitro studies—regulatory role of FR255734 on activated
T cells
Effect of FR255734 on T-cell proliferation. Peripheral blood
mononuclear cells were isolated from blood samples, obtained with
informed consent from healthy volunteers, by Ficoll–Hypaque
density centrifugation. These experiments were performed at both
Astellas Pharmaceuticals Inc. and Stanford University, USA. Blood
was obtained after getting informed consent signed. These studies
adhered to the Declaration of Helsinki Principles. Human T cells
were purified from PBMCs using nylon fiber column (Wako, Osaka,
Japan). Purity was 495%, checked by flow cytometry using anti-
CD3 antibody conjugated with pacific blue fluorochrome. A total of
1 105 T cells were cultured with 1 ngml1 of anti-CD3 antibody
(clone, OKT3; Janssen Pharmaceutical, Tokyo, Japan) and 1 105
irradiated cells of human CD80 expressing mouse mastocytoma cell
line (hCD80/P815) for 3 days. FR255734, mouse, and the human
isotype control, IgG2 (both mouse and human IgG2 were gifts to the
Principal Investigator of this project from Dr Keting Chu, Department
of Infectious Diseases, Stanford University School of Medicine),
were added to the culture concomitant with stimulation. To evaluate
proliferation of T cells, 6 hours before termination of culture, wells
were pulsed with 0.27 mCi of 3H-labeled thymidine (Moravek
Biochemicals, Brea, CA) and incorporation was measured using a
b-counter.
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Cytokine assay by ELISA to investigate the inhibitory effect
of FR255734 on T-cell function. Peripheral blood mononuclear
cells were stimulated with anti-human CD3CD28 antibodies (BD
Pharmingen, San Diego, CA) and tetanus toxoid, a recall antigen
(Wyeth-Ayerst Pharmaceuticals, Madison, NJ). Wells of a 24-well
plate were coated with human anti-CD3 and CD28 antibodies
(5mgml1 each) by overnight incubation at 4 1C, then wells were
washed with complete medium (RPMI-1640 with 10% human AB
serum, penicillin streptomycin, and glutamine). One million PBMCs
in 1ml of complete medium were cultured in these wells for
72 hours. Each set of experiments consisted of three wells without
CD3CD28 antibodies; three wells with CD3CD28 antibodies;
three CD3CD28 coated wells with FR255734 antibody, 300 ngml1;
three CD3CD28 coated wells with mouse IgG2, 300 ngml1; three
CD3CD28 antibody coated wells with human IgG2, 300 ngml1
and three CD3CD28 coated wells with CTLA4-Ig antibody,
0.2 ngml1 (positive control); and three wells coated with
CD3 antibody alone. After 72-hour incubation, supernatants
were collected and stored for IFN-g and IL-2 assay by ELISA
(Endogen-Pierce, Woburn, MA). Similar experiments were per-
formed using tetanus toxoid (732 ngml1 per well) to stimulate T
cells, and in combination with FR255734, isotype controls, and
CTLA4-Ig to determine the effect of FR255734 on recall antigen
responses. These experiments were performed using PBMCs from six
volunteers. This part of in vitro studies was carried out at Stanford
University.
In vivo studies
Establishment of psoriasis SCID xenograft model. Human
psoriasis plaques were transplanted on to the SCID mice. This study
was approved by the Stanford University Institutional Review Board.
These studies adhered to the Declaration of Helsinki Principles.
Patients were recruited and evaluated at the Dermatology Clinic at
Stanford University School of Medicine. The patients had general-
ized plaque psoriasis involving 5–10% of the total skin. They did not
receive any systemic treatment for psoriasis or phototherapy in the
past 6 months and did not receive any topical preparations other
than emollients in past 6 weeks. Shave biopsies (2.5 2.5 cm)
were obtained from active plaques located on the thigh or arm
of 20 psoriatic patients. Each piece of biopsy was divided into
four equal parts of approximately 1 cm2 size. Thus, 80 SCID mice
were transplanted using shave the biopsies obtained from
20 patients.
CB17 SCID mice were purchased from Jackson Laboratory (Bar
Harbor, ME) and housed at the Stanford University Research Animal
Facility (Palo Alto, CA) in a pathogen-free environment. The Animal
Experimental Protocol Review Committee of Stanford University
approved the protocol for animal experiments. Under general
anesthesia, a graft bed of approximately 1 cm2 was created on the
shaved area of the back of a 7- to 8-week-old mouse by removing a
full-thickness skin sample, keeping the vessel plexus intact on the
fascia covering the underlying back muscles. The partial thickness
human skin obtained by shave biopsy was then orthotopically
transferred onto the graft bed. Nexaband, a liquid veterinary
bandage (Veterinary Products Laboratories, Phoenix, AZ) was used
to attach the human skin to the mouse skin and an antibiotic
ointment (bacitracin) was applied. The psoriatic grafts were accepted
in approximately 3–4 weeks.
Methodologies for evaluation of therapeutic efficacy of
FR255734. Punch biopsies (2mm) were obtained on day 0 (before
treatment) and day 28 (after treatment) of the study period. Biopsies
were snap frozen and cryosections were made for histopathological
and immunohistochemical studies: (i) hematoxylin and eosin
staining was performed on sections obtained from the biopsies to
determine rete peg length, an indicator of epidermal thickness; (ii)
immunocytochemical staining was performed using rabbit poly-
clonal anti-human CD3, HLA-DR, TNF-a, and ICAM-1 antibodies
obtained from Santa Cruz Biotechnology, Santa Cruz, CA. Immuno-
histochemical staining methodologies were as per our standardized
earlier publications (Raychaudhuri et al., 2001, 2004). Therapeutic
efficacy was determined by comparing pre- and post treatment data:
(i) rete peg lengths to determine the effect on epidermal thickness
and (ii) the level of lymphomononuclear cell infiltrates to determine
the effect on inflammatory cellular infiltrates.
Treatment regimen. FR255734, isotype controls (mouse and
human IgG2), saline, and CTLA4-Ig were administered intraperito-
neally once a week for 4 weeks (Table 2). Cyclosporine was
administered 3 times per week for 4 weeks.
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